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Consumption of fish or fish oils rich in the n-3 long chain PUFA EPA and DHA may improve multiple risk factors for CVD. The objective of this
study was to determine whether regular consumption of foods enriched with n-3 long-chain PUFA can improve n-3 long-chain PUFA status
(erythrocytes) and cardiovascular health. Overweight volunteers with high levels of triacylglycerols (TG; .1·6mmol/l) were enrolled in a
6-month dietary intervention trial conducted in Adelaide (n 47) and Perth (n 39), and randomised to consume control foods or n-3-enriched
foods to achieve an EPA þ DHA intake of 1 g/d. Test foods were substituted for equivalent foods in their regular diet. Erythrocyte fatty
acids, plasma TG and other CVD risk factors were monitored at 0, 3 and 6 months. There were no significant differences between groups for
blood pressure, arterial compliance, glucose, insulin, lipids, C-reactive protein (CRP) or urinary 11-dehydro-thromboxane B2 (TXB2) over
6 months, even though regular consumption of n-3-enriched foods increased EPA þ DHA intake from 0·2 to 1·0 g/d. However, the n-3 long-
chain PUFA content of erythrocytes increased by 35 and 53% at 3 and 6 months, respectively, in subjects consuming the n-3-enriched foods.
These increases were positively associated with measures of arterial compliance and negatively associated with serum CRP and urinary 11-dehy-
dro-TXB2 excretion. Sustainable increases in dietary intakes and erythrocyte levels of n-3 long-chain PUFA can be achieved through regular con-
sumption of suitably enriched processed foods. Such increases may be associated with reduced CV risk.
Functional foods: n-3 Long-chain polyunsaturated fatty acids: Processed foods: Dietary intervention: Cardiovascular disease
The CVD health benefits of n-3 long-chain PUFA consump-
tion have been demonstrated in experimental animal and
human studies, resulting in approval by the US Food and
Drug Administration of a qualified health claim for n-3
long-chain PUFA and coronary heart disease (USFDA,
2004). A high n-3 long-chain PUFA status is thought to be
cardioprotective through reduction of risk factors such as
dyslipidaemia, hypertension, thrombosis and arrhythmia
(McLennan et al. 1996; Hu & Willet, 2002; Wijendran &
Hayes, 2004) and improvement of arterial compliance, endo-
thelial vasodilator function (Nestel et al. 2002) and heart
rate variability (Christensen, 2003). In the GISSI-Prevenzione
study, a large-scale intervention trial in post-myocardial
infarction patients, supplementation with 850mg/d n-3 long-
chain PUFA reduced total mortality, cardiovascular mortality
and, specifically, sudden cardiac death (GISSI-Prevenzione
Investigators, 1999). To maintain cardiovascular health, the
American Heart Association recommends eating at least two
fatty-fish meals per week, equalling 400–500mg/d n-3 long-
chain PUFA. The International Society for the Study of
Fatty Acids and Lipids recommends consuming at least
500mg/d of EPA and DHA, and the Australian National
Health and Medical Research Council recommends consum-
ing 410mg/d for women and 630mg/d for men (Baghurst,
2005). Countries with a high fish intake readily achieve this
target, e.g. average n-3 long-chain PUFA consumption in
Japan is 1·6 g/d (Dolecek, 1992). However, these recommen-
dations may be difficult to attain in countries with traditionally
low fish intake such as the USA and Australia, where median
n-3 long-chain PUFA intakes are only 100 and 140mg/d,
respectively (Meyer et al. 2003).
An alternative strategy to increase the n-3 long-chain PUFA
status of the population is to expand the range of foods con-
taining n-3 long-chain PUFA. A variety of foods including
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chicken meat (Lopez-Ferrer et al. 2001), pork (Howe et al.
2002), eggs (Lewis et al. 2000), bread (Yep et al. 2002),
spreads (Roche & Gibney, 1994; Kolanowski et al. 2001)
and other processed products (Lovegrove et al. 1997; Metcalf
et al. 2003) have now been enriched with n-3 long-chain
PUFA. However, there has been little evaluation of the poten-
tial contribution of these foods to increased population n-3
intakes. We conducted a double-blind, parallel, dietary inter-
vention trial of 6 months duration at two sites in Australia,
Adelaide and Perth, to examine the feasibility and anticipated
cardiovascular benefits of increasing habitual n-3 long-chain
PUFA intake to 1 g/d through regular consumption of a variety
of n-3 long-chain PUFA food sources.
Materials and methods
Subjects
Ninety-four men and women aged 20–65 years, who were
overweight and had fasting plasma triacylglycerols (TG)
.1·6mmol/l, were recruited through local media advertise-
ments in Perth and Adelaide to participate in a 6-month
double-blind, randomized, parallel comparison of the effects
of consuming enriched or control foods. Subjects were
excluded if they reported one of the following: diagnosed dia-
betes mellitus, recent symptomatic heart disease including
angina pectoris; history of myocardial infarction or stroke;
peripheral vascular disease; major surgery within the last 3
months; blood pressure (BP) .160/100mmHg; liver or
renal disease (plasma creatinine .120mmol/l); regular non-
steroidal anti-inflammatory, antihypertensive or hypocholes-
terolaemic drug therapy; eating more than one fish meal per
week or taking fish oil supplements; and inability to consume
the test foods. Of ninety-four volunteers who attended screen-
ing, eighty-six were stratified according to baseline TG con-
centration and BMI, and randomly allocated to one of two
groups. The study was approved by the Human Research
Ethics Committees at the University of Western Australia,
the University of Adelaide and the CSIRO. All participants
gave written informed consent.
n-3-enriched foods
Foods enriched with n-3 long-chain PUFA and matching con-
trol foods, including cheese spread, chocolates, instant oats,
milk, dips (pepper, tzatziki, salsa), biscuits (Anzac and
ginger), pancakes, muffins, bread, salad dressing and dry
soup mix (chicken laksa and vegetable) were provided by
Goodman Fielder Ltd, Sydney, Australia. Processed foods
were enriched with blended or microencapsulated cod fish
oil provided by Maritex, Aarhus, Denmark. Regular eggs or
Omega-3 Eggs were obtained from Pace Farm Pty Ltd,
Sydney, Australia. The EPA and DHA contents of these
foods are shown in Table 1.
Study design—food consumption and diet analysis
Participants were asked to consume eight servings of study
foods per day for 6 months. Each serving of the n-3-enriched
foods was intended to provide approximately 125mg EPA þ
DHA, i.e. a total of 1 g of n-3 PUFA/day. Subjects were
advised to replace customary foods with study food equiva-
lents. Intervention foods (enriched with n-3 long-chain
PUFA; omega-3 group) and equivalent control foods (not
enriched; control group) were supplied to all subjects in
unmarked packages. The identity of the study foods was
blinded to the subjects as well as the researchers conducting
the intervention. Subjects were provided with 2 weeks
supply of study foods and instructed on how to incorporate
eight portions of study foods into their ad libitum background
diet.
Table 1. Content (mg/serving) of n-3 long-chain PUFA in n-3-enriched
foods and control foods
Food (serving size) EPA (20: 5n-3) DHA (22: 6n-3) EPA þ DHA
Anzac biscuit (2 biscuits, ,40 g)
Control 1 1 2
Omega 46 65 111
Ginger biscuit (2 biscuits, ,40 g)
Control ND 1 1
Omega 48 71 119
Bread (2 slices, ,90 g)
Control ND ND ND
Omega 45 58 103
Cheese spread (15 g)
Control 3 1 4
Omega 48 66 114
Chocolate (25 g)
Control ND ND ND
Omega 17 24 42
Tomato salsa dip (25 g)
Control ND ND ND
Omega 40 57 97
Cracked pepper dip (30 g)
Control 5 1 6
Omega 53 71 124
Tzatziki dip (30 g)
Control 1 1 2
Omega 40 56 96
Egg (2, ,90 g)
Control 1 61 62
Omega 12 146 158
Margarine (20 g)
Control ND ND ND
Omega 61 85 146
Skim milk (250 ml)
Control ND ND ND
Omega 33 55 89
Muesli (30 g)
Control 1 ND 1
Omega 6 7 13
Muffin (,75 g)
Control ND ND ND
Omega 63 88 151
Porridge (30 g)
Control 1 ND 1
Omega 3 ND 3
Pancake (3 pikelets, ,30 g)
Control ND ND ND
Omega 23 32 55
Salad dressing (40 ml)
Control 4 2 7
Omega 40 53 93
Laksa soup mix (1 sachet, ,85 g)
Control 4 7 11
Omega 152 219 371
Vegetable soup mix (1 sachet, ,85 g)
Control ND 1 1
Omega 187 255 442
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Subjects were seen every second week to monitor body
weight, collect study foods and to discuss any issues arising
from the intervention. Daily logs of study food consumption
were kept by each subject to monitor the number of servings
and types of foods consumed. However, after the first month
of the study, those subjects who gained weight were advised
by a qualified dietitian on strategies to reduce their energy
intake whilst accommodating the study foods. This was mon-
itored throughout the study. Subjects completed a diet history
questionnaire and 3 d weighed food records (two weekdays
and one weekend day) at baseline, 3 months and 6 months.
Details of the dietary collection methods have been described
previously by Patch et al. (2005). Dietary data were entered
into the Foodworkse nutrient analysis software package
(Xyris Software, Highgate Hill, Brisbane Australia, Pro-
fessional Version 3.2, 2002), using the Australian nutrient
database AusNut Rev 0.14 (AusNut 2000, Department of
Human Services & Health, Canberra) and Australian Fatty
Acids Rev 0·6 (Royal Melbourne Institute of Technology,
2002) to derive values for energy, macronutrient intakes and
fatty acids. Data on consumption of all study foods (control
and n-3-enriched) were entered into the Foodworkse data-
base. Nutrient content was analysed through recipe analysis
using product information and analytical data from microen-
capsulated fish oil powder used in the products. Where
foods reported were not found listed in the database, data on
equivalent food items were used.
Study design—clinic visits
Subjects attended the clinic on two consecutive days at base-
line and after 3 and 6 months of intervention, and the follow-
ing assessments were made at each time point unless stated
otherwise. Weight was recorded to calculate BMI (kg/m2;
height was measured at baseline only). Waist circumference
(midway between the lower rib and iliac crest) and hip cir-
cumference (at greater trochanter) were measured with a
metric tape to calculate the waist to hip ratio (WHR). A
fasted blood sample was taken on each of the two consecutive
clinic days and a 24 h urine sample was collected between the
two clinic days (see below).
Subjects were instructed to lie supine for 10min in a quiet
temperature-controlled (248C) room prior to measurement of
BP and arterial compliance using a PulseWave CR-2000
instrument (HDI, Egan, MN, USA). Arterial compliance cal-
culates compliance from the spatial difference between the
incident and reflected BP peaks, differentiating between
the large and small arteries. It refers to the degree to which
the internal diameter of the artery changes in response to
alterations in intravascular pressure. Systolic and diastolic
BP, heart rate and indices of compliance in proximal (large
capacitance) arteries (C1) and distal (small resistance) arteries
(C2) were derived from a series of three measurements con-
ducted at 5min intervals.
Erythrocyte fatty acids
Erythrocytes were isolated from whole blood, washed with
isotonic saline (0·9%), frozen, thawed then lysed in hypotonic
0·01-M Tris EDTA buffer, pH 7·4. A membrane pellet was
obtained by ultracentrifugation (50 000 g for 30min) from
which lipids were extracted and transmethylated according
to the method of Lepage & Roy (1986). Fatty acid methyl
esters were analysed using a Shimadzu gas chromatograph
20A (Shimadzu Corporation, Kyoto, Japan) fitted with a
flame ionisation detector and a 50m BPX70 column
(0·32mm id and 0·25mm film thickness; SGE, Australia).
Samples were injected at 1508C and held for 0·5min. The
oven temperature was increased at 48C/min to 2008C, then
at 28C/min to a final temperature of 2308C which was held
for 2min. The injector and detector were maintained at
2608C and hydrogen was used as the carrier gas. Individual
fatty acids were identified by comparison with known stan-
dards (Nuchek Prep Inc., Elysian, MN, USA) and expressed
as a percentage of total fatty acids quantified from peak areas.
Urinary 11-dehydro thromboxane B2 and creatinine
The 24 h urine samples were collected with preservative
(15mg of indomethacin). An aliquot was assayed for the
thromboxane A2 metabolite 11-dehydro-thromboxane B2
(TXB2) by the method of Perneby et al. (1999) with modifi-
cations, which reflects platelet activity in vivo. Briefly, urine
(1ml) was incubated at room temperature with 63-mM
Ambic buffer pH 8·6 (2ml) for 3 h to hydrolyse the d-lactone
ring of 11-dehydro-TXB2. The urine was applied to Bond
Elute Certify II columns (Varian) conditioned with methanol
(2ml) and water (3ml), and washed with 0·63-mM Ambic
buffer (3ml), water (3ml) and methanol (6ml). The 11-dehy-
dro-TXB2 was eluted with 2% formic acid in methanol (2ml),
dried, resuspended in 0·5ml of immunoassay buffer and
assayed in duplicate with one dilution, using a 11-dehydro-
TXB2 enzyme immunoassay system (Cayman Chemical Co.,
Ann Arbor, MI, USA). Urinary thromboxane was expressed
as ng/24 h or corrected for creatinine levels. Creatinine
levels were measured using a commercially available kit on
an autoanalyser (Roche Diagnostica, Basel, Switzerland).
Plasma lipids and high sensitive C-reactive protein (hsCRP)
Plasma total cholesterol, TG and HDL-cholesterol were deter-
mined enzymatically on the Cobas MIRA analyser (Roche
Diagnostica, Basel, Switzerland) with reagents from Trace
Scientific (Melbourne, Australia). In order to measure HDL-
cholesterol, the non-HDL lipoproteins were precipitated
using heparin–manganese (Warnick & Albers, 1978).
LDL-cholesterol was calculated using the Friedewald formula
(Friedewald et al. 1972). Samples were measured in a single
assay to minimise inter-assay variation. Plasma hsCRP was
measured by solid-phase chemiluminescent assay (Diagnostic
Products Corporation, Los Angeles, CA, USA).
Plasma glucose and insulin
Plasma glucose concentrations were measured on a Cobas-Bio
centrifugal analyser (Roche Diagnostica, Basel, Switzerland)
using a commercial enzymatic kit (Roche Diagnostics,
Australia). Plasma insulin concentrations were determined
using an enzyme-linked immunosorbent assay kit (Merccolia,
American Laboratory Products Company, New Hampshire,
USA).
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Statistical analysis
Based on previous determinations of the variance in a primary
outcome measure, namely the change of plasma TG, we esti-
mated that a total of ninety subjects would give 90% power to
observe a significant (P,0·05) reduction of 0·2mM in plasma
TG. Data were analysed using repeated measures ANOVA
with post hoc analyses where significance was seen. Analysis
focused on changes in variables from baseline to 3 and 6
months. Correlations between dietary intakes of n-3 long-
chain PUFA, erythrocyte levels of individual (EPA, docosa-
pentaenoic acid and DHA) and total n-3 long-chain PUFA
and cardiovascular risk factors were examined using SPSS
12·1 (SPSS, Chicago, IL, USA) or SAS 9.1 (SAS Institute,
Cary, NC, USA). End-points were determined using Mixed
Models (Proc Mixed, SAS) adjusting for study site, with sub-
ject as a random effect and treatment group as a fixed effect.
Significance was set at P,0·05 unless otherwise stated.
Results
Subject characteristics
There were no significant differences in age, height, weight,
BMI and WHR between the two treatment groups at baseline
(Table 2). However, weight increased progressively during the
intervention (1·1% after 3 months and 1·8% after 6 months;
P,0·001, paired t test), with no difference between treatment
groups. Of the ninety-four subjects initially enrolled in the
study, six withdrew prior to commencement and two withdrew
at commencement, one due to dislike of the foods and the
other for personal reasons. Thus eighty-six subjects (n 44, con-
trol group and n 42, omega-3 group) proceeded with the inter-
vention, but twelve withdrew between 3 and 6 months, due to
dislike of the study foods, changes in employment, health or
lost to follow-up. Hence seventy-four subjects (n 36 control
group and n 38 omega-3 group) completed the full 6-month
intervention period.
Food consumption and n-3 intake
There was no significant difference between treatment groups
in the amounts of foods consumed or in the consumption of
any type of food other than those allocated. No side effects
from consumption of either n-3-enriched or control foods
were reported. Daily logs and food compliance questionnaires
revealed that both groups consumed between 6 and 7·5 ser-
vings/d of the study foods, slightly below the target of 8 ser-
vings/d, but sustained throughout the 6-month study period.
However, as seen in Table 1, the actual EPA þ DHA content
of randomly sampled n-3-enriched foods varied markedly
from the intended 125mg/serving. These variations were
taken into account in estimating individual intakes of fatty
acids from weighed food records, as described elsewhere
(Patch et al. 2005).
There were no significant differences in EPA and DHA
intakes between the two groups at baseline (Table 3). There
was no significant change in the control group during the
intervention, but n-3 long-chain PUFA intake increased from
0·2 to 1·0 g/d in the omega-3 group. After 6 months, the
major sources of n-3 long-chain PUFA-enriched foods in the
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(both fatty and white) remained the major source of n-3 long-
chain PUFA in the control group, averaging approximately
one serving per fortnight (,0·1 g/d).
At the end of the study, participants rated the acceptability
of the study foods on a 7-point Likert scale ranging from 23
(extremely dislike) to þ3 (extremely like) as described else-
where (Patch et al. 2005). The omega-3 group rated the oats
and milk slightly favourably (1·4 and 0·5, respectively)
whereas they rated the bread as quite unfavourable (20·3),
which was significantly different (P,0·05) from the control
group (1·1). The salad dressing was also rated unfavourably
(20·3 for both groups). All other food items were rated
favourably with no reported significant differences between
the groups. There were no major differences in macronutrient
intakes between groups (Patch et al. 2005).
Erythrocyte EPA and DHA levels
Total n-3 long-chain PUFA content of erythrocytes in the
omega-3 group increased by 43 and 60% at 3 and 6 months
of the intervention, respectively (P,0·05). EPA and DHA
content of erythrocytes increased by 82 and 53%, respect-
ively, at 3 months and by 111 and 76% at 6 months
(P,0·05) (Table 4). There were no changes in n-3 long-
chain PUFA content of erythrocytes in the control group.
Erythrocyte EPA and DHA levels were not related to
intakes at baseline in the whole group (n 80) perhaps due to
the difficulties in dietary assessment methodology (Patch
et al. 2005). However, there was a significant correlation
between the calculated intake of EPA þ DHA from foods
and erythrocyte levels of EPA þ DHA in individuals at 3
months (r 0·35; P,0·01), which became stronger after 6
months (r 0·69; P,0·001), reflecting the progressive incorpor-
ation on PUFA from food into erythrocytes.
Cardiovascular risk factors
There was no significant difference between omega-3 and con-
trol groups in the effects of the intervention for 3 or 6 months
on the following parameters: systolic and diastolic BP, com-
pliance of small or large arteries, blood glucose, insulin, lipo-
protein lipids (total, HDL and LDL cholesterol and TG), CRP
or urinary 11-dehydro-TXB2 (Table 5). However, when using
mixed model analyses that included all three time points (0, 3
and 6 months) and adjusted for weight changes and study site,
there were significant positive associations between erythrocyte
total n-3 long-chain PUFA (EPA þ docosapentaenoic acid þ
DHA) and both small (C1) (log likelihood ¼ 1162, P¼0·02)
and large (C2) (log likelihood ¼ 1380, P¼0·08) artery compli-
ance, and negative associations between erythrocyte n-3 long-
chain PUFA and serum CRP (log likelihood ¼ 340, P¼0·006)
and urinary 11-dehydro-TXB2 (creatinine adjusted) (log
likelihood ¼ 502, P¼0·08). Furthermore, erythrocyte DHA was
positively associated with C1 (log likelihood ¼ 1156, P¼0·04)
andC2 (log likelihood ¼ 1372,P¼0·07) and inversely associated
with serum CRP (log likelihood ¼ 339, P¼0·02). Erythrocyte
EPA was positively associated with small artery compliance
(log likelihood ¼ 1153, P¼0·07) and LDL-cholesterol (log
likelihood ¼ 618, P¼0·07).
Interestingly, there was a positive correlation between the
change in weight and the change in plasma TG from 0 to 3
months in the control group (P,0·05) but not the omega-3
group (P¼0·25); this pattern of results was also obtained
between 3 and 6 months.
Discussion
Subjects in the present study had baseline intakes of n-3 long-
chain PUFA (155–200mg/d) typical of the Australian popu-
lation (Ollis et al. 1999; Meyer et al. 2003; Howe et al.
2006). We were successful in encouraging those in the
omega-3 group to increase their n-3 long-chain PUFA intake
to 1 g/d by replacing habitual foods with a variety of n-3-
enriched study foods. Moreover, we found that this 5-fold
increase in n-3 long-chain PUFA intake could be maintained
for a long duration (i.e. 6-month intervention period) by utilis-
ing n-3 food sources other than fish.
This increase in regular consumption of n-3 long-chain
PUFA resulted in a progressive increase in the n-3 long-
chain PUFA content of erythrocytes, as observed by others
(Mantzioris et al. 2000; Wallace et al. 2000; Metcalf et al.
2003). The EPA þ DHA content of erythrocytes rose from
4 to 7% of total fatty acids, placing these subjects in a
lower risk category for cardiac death, according to the
Omega-3 Index suggested by Harris & Von Schacky (2004).
The Omega-3 Index relates to the level of EPA and DHA in
erythrocytes and risk of sudden cardiac death; a high level
of EPA þ DHA is associated with greatest protection from
sudden cardiac death. The Omega-3 Index is supported by
Table 3. Fatty acid intakes (g/d)
(Mean values with their standard errors)
Control (n) Omega-3 (n)
Baseline (44) 3 months (40) 6 months (32) Baseline (42) 3 months (39) 6 months (32)
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Total fat 81·1 6·4 83·6 4·4 88·1 5·8 87·5 5·6 89·1 4·7 101·2 4·8
n-6 PUFA 10·3 0·7 11·8 0·9 12·1 0·8 10·4 0·7 10·5 0·7 14·3 0·9
n-3 PUFA 1·3 0·1 2·1 0·2 1·8 0·1 1·6 0·1 3·0 0·2 3·6 0·3
EPA 0·05 0·01 0·06 0·01 0·03 0·01 0·06 0·02 0·41 0·02* 0·37 0·04*
DHA 0·09 0·03 0·13 0·03 0·09 0·01 0·13 0·02 0·65 0·02* 0·59 0·06*
EPA þ DHA 0·15 0·04 0·19 0·04 0·11 0·03 0·20 0·04 1·06 0·04* 0·96 0·11*
* Significant change over time (repeated measures ANOVA).
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Table 4. Fatty acid composition of erythrocytes (% of total fatty acids)
(Mean values with their standard errors)
Control (n) Omega-3 (n)
Baseline (44) 3 months (44)
D 0–3 months
(44) 6 months (35)
D 0–6 months
(35) Baseline (42) 3 months (42)
D 0–3 months
(42) 6 months (38)
D 0–6 months
(38)
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Total SFA 47·5 0·7 46·0 0·4 –1·5 0·7 46·8 0·6 –0·3 1·0 48·3 0·9 46·7 0·5 –1·7 0·7 46·4 0·5 –2·2 0·8
Total MUFA 20·2 0·4 19·9 0·2 –0·3 0·4 19·6 0·3 –0·2 0·5 20·5 0·4 20·0 0·2 –0·4 0·4 19·5 0·2 –1·2 0·4
Total PUFA 28·7 1·1 31·4 0·6 2·6 1·0 30·6 1·0 1·1 1·6 28·0 1·2 30·9 0·7 2·9 1·1 31·5 0·7 4·0 1·2
n-6 PUFA 22·2 0·8 24·3 0·5 2·1 0·7 23·8 0·7 –0·1 1·3 22·0 0·9 22·3 0·5 0·3 0·8 22·1 0·4 0·4 0·9
LA (18 : 2n-6) 6·9 0·2 7·2 0·2 0·3 0·1 7·3 0·2 0·3 0·2 6·9 0·2 6·9 0·1 0·1 0·1 7·0 0·1 0·1 0·1
AA (20 : 4n-6) 11·1 0·5 12·5 0·3 1·4 0·5 12·0 0·5 0·6 0·7 11·0 0·6 11·5 0·3 0·4 0·6 11·5 0·3 0·6 0·6
n-3 PUFA 6·6 0·4 7·1 0·2 0·5 0·3 6·8 0·3 –0·1 0·5 6·0 0·3 8·6 0·3* 2·6 0·3 9·4 0·3* 3·6 0·4
EPA (20 : 5n-3) 0·61 0·04 0·64 0·03 0·03 0·03 0·63 0·03 –0·01 0·05 0·55 0·04 1·0 0·05* 0·45 0·05 1·2 0·06* 0·61 0·06
DPA (22 : 5n-3) 2·0 0·11 2·2 0·07 0·2 0·1 2·2 –0·10 0·04 0·14 1·97 0·12 2·2 0·08 0·3 0·1 2·3 0·08 0·4 0·1
DHA (22 : 6n-3) 3·8 0·23 4·1 0·13 0·2 0·2 3·9 0·20 –0·1 0·3 3·42 0·20 5·3 0·20* 1·8 0·2 5·9 0·20* 2·6 0·2
SFA, saturated fatty acids; LA, linoleic acid; AA, arachidonic acid; DPA, docosapentaenoic acid.
* Significant change over time (repeated measures ANOVA).
Table 5. Arterial compliance, blood pressure and biochemical indices
(Mean values with their standard errors)
Control (n) Omega-3 (n)
Baseline 3 months D 0–3 months 6 months D 0–6 months Baseline 3 months D 0–3 months 6 months D 0–6 months
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
C1 16·0 0·7 (42) 16·8 0·8 (42) –0·06 0·31 (44) 16·4 0·9 (36) – 0·26 (36) 17·8 0·9 (40) 17·4 0·7 (40) 0·05 0·32 (42) 18·0 0·8 (38) –0·46 0·33 (38)
C2 6·8 0·6 (42) 6·8 0·6 (42) 0·57 0·47 (44) 6·1 0·5 (36) 0·63 0·61 (36) 7·3 0·5 (40) 7·4 0·5 (40) –0·42 0·63 (42) 6·9 0·5 (38) 0·15 0·83 (38)
SBP (mmHg) 129 3·5 (42) 127 3·4 (42) 1·48 1·67 (44) 131 1·8 (36) –0·9 3·75 (37) 130 3·4 (40) 127 3·4 (40) 2·35 1·34 (42) 127 3·7 (38) 2·85 1·51 (38)
DBP (mmHg) 73 2·2 (42) 74 2·3 (42) 1·13 0·96 (42) 76 1·5 (36) 1·7 1·4 (35) 72 2·2 (40) 73 2·3 (40) 1·22 0·98 (40) 76 1·5 (38) 2·2 0·93 (38)
GLU (mmol/l) 5·5 0·1 (44) 5·4 0·1 (44) –0·09 0·07 (44) 5·5 0·1 (36) 0 0·09 (36) 5·4 0·1 (42) 5·4 0·1 (42) 0·02 0·06 (42) 5·5 0·1 (38) 0·12 0·07 (38)
Insulin (mU/l 12·8 1·8 (44) 13·0 1·2 (44) 0·19 1·62 (44) 13·1 1·4 (36) 0·48 1·87 (36) 14·2 1·1 (42) 14·6 1·3 (42) 0·37 0·88 (42) 14·7 1·3 (38) 0·9 0·7 (38)
TC (mmol/l 5·7 0·2 (44) 5·6 0·2 (44) –0·1 0·08 (44) 5·8 0·2 (36) 0·05 0·08 (36) 5·5 0·2 (41) 5·8 0·2 (41) 0·22 0·12 (41) 5·6 0·2 (38) 0·17 0·1 (38)
TG (mmol/l 1·9 0·1 (44) 1·9 0·1 (44) 0·07 0·08 (44) 2·0 0·2 (36) 0·09 0·11 (36) 1·8 0·1 (42) 2·0 0·1 (42) 0·19 0·1 (41) 1·8 0·1 (38) –0·02 0·08 (38)
LDL (mmol/l) 3·7 0·1 (44) 3·6 0·1 (44) –0·15 0·07 (44) 3·7 –0·2 (36) –0·03 0·07 (36) 3·6 0·2 (41) 3·8 0·1 (41) 0·12 0·1 (41) 3·7 0·1 (38) 0·16 0·08 (38)
HDL (mmol/l) 1·16 0·06 (44) 1·16 0·05 (44) 0 0·02 (44) 1·14 0·05 (36) 0·03 0·02 (36) 1·08 0·04 (41) 1·10 0·06 (41) 0·02 0·02 (41) 1·09 0·06 (38) 0·02 0·03 (38)
CRP (mg/l) 3·9 0·4 (44) 4·6 0·7 (44) 0·74 0·75 (44) 5·1 0·8 (36) 1·29 0·71 (36) 5·2 0·7 (42) 4·3 0·8 (42) –0·91 0·63 (42) 5·6 1·0 (38) 0·38 0·88 (38)
U TXB2
(ng/24 h)
402 53 (43) 444 49 (42) 34 60 (42) 509 59 (36) 106 58 (36) 365 49 (40) 381 45 (39) 23 55 (39) 401 44 (38) 20 48 (38)
C1, small artery compliance; C2, large artery compliance; SBP, systolic blood pressure; DBP, diastolic blood pressure; GLU, glucose; TC, total cholesterol; TG, triacylglycerols; CRP, C-reactive protein;















a number of clinical studies that have shown the benefits of n-
3 long-chain PUFA such as the GISSI-Prevenzione trial
(GISSI-Prevenzione Investigators, 1999), in which an n-3
long-chain PUFA supplement of 1 g/d over 3 years reduced
the risk of sudden cardiac death by 45% in men with a pre-
vious myocardial infarction. The emergence of a correlation
between intakes and erythrocyte levels of EPA þ DHA
after baseline could well reflect the high variability in habitual
n-3 long-chain PUFA intakes prior to intervention and the
greater consistency of n-3 long-chain PUFA intakes achieved
subsequently from regular consumption of the study foods.
Weber & Raederstorff (2000) suggested that a dose of
approximately 1 g/d of n-3 long-chain PUFA is the smallest
necessary for a TG-lowering effect. Consistent with this, the
0·8 g/d increase in n-3 long-chain PUFA intake achieved in
the present study by consuming a variety of n-3-enriched
foods failed to improve plasma TG or HDL-cholesterol
levels. It is well known that high intakes of fish oils (,3 g/
d) can lower plasma TG in hypertriglyceridaemic subjects
(Calabresi et al. 2004). Reductions have been reported at
much lower doses (,1 g/d) in both hypertriglyceridaemic sub-
jects (Junker et al. 2001) and normotriglyceridaemic subjects
(Roche & Gibney, 1996; Visioli et al. 2000). However, in
another study with n-3-enriched foods (Lovegrove et al.
1997), healthy males were given foods providing ,1·4 g/d
of n-3 long-chain PUFA for 22 d then crossed over to the
equivalent unenriched foods for a further 22 d after a 5-
month washout period. They reported an increase of HDL-
cholesterol but no change in plasma TG. On the other hand,
Visioli et al. (2000) showed that consuming 500ml of skim
milk enriched with n-3 long-chain PUFA (300mg of EPA
þ DHA) resulted in a 19% reduction of plasma TG and a
19% increase in HDL-cholesterol in normolipidaemic volun-
teers. The lack of effect on plasma TG in our study may be
attributed to the marginal increase in n-3 long-chain PUFA
intake, falling short of a 1 g/d threshold.
Any effect of n-3 long-chain PUFA on plasma TG in this
study may have been masked by the weight gain observed
in both groups during the 6-month intervention. Other studies
have also failed to see a reduction in plasma TG when the sub-
jects also gained weight (Lovegrove et al. 1997).
An HDL-raising effect of fish oils has been shown in some,
but not all studies. A study by Laidlaw & Holub (2003) used a
4 g dose of fish oil for 28 d, which resulted in a 7–10%
increase in HDL-cholesterol in healthy women. However, in
subjects with combined hyperlipidaemia supplemented with
3·4 g EPA þ DHA (Omacor), there was no HDL-choles-
terol-raising effect.
Compared with the effects of fish oil supplementation, other
studies where n-3 long-chain PUFA were provided in foods
have shown mixed results. HDL-cholesterol did not increase
significantly in a cross-over study in which hypertriglyceridae-
mic subjects consumed 1·6 g/d of n-3 long-chain PUFA for
3 weeks (Junker et al. 2001). However, in the cross-over
study by Lovegrove (1997), consumption of n-3 long-chain
PUFA-enriched foods for 22 d resulted in a significant increase
in HDL-cholesterol. All these studies were of short duration
and, as in our long-term study, no significant HDL-choles-
terol-raising effect was seen. The effect of diet on
HDL-cholesterol, however, is likely to be due to the overall
composition of the diet, and not just one nutrient (or a few
foods), so the apparent ambiguity seen in these studies could
also be due to lack of control in the background diet.
The likely reason for the lack of effect of n-3 long-chain
PUFA on either BP or arterial compliance is the relatively
low intake of n-3 long-chain PUFA in the present study. In
a meta analysis of studies of 3–24 weeks duration, intakes
of 3–5·6 g/d were effective in reducing BP by between 3·4/
2·0 and 5·5/3·5 mmHg in hypertensive subjects (Geleijnse
et al. 2002). Furthermore, our study population were mainly
normotensive and the effects of fish oils on BP are usually
seen in hypertensive individuals. Similarly, improvements in
arterial compliance have been observed at intakes comparable
with those that have reduced BP (Nestel et al. 2002). How-
ever, even with the lower intakes achieved in our study,
there was a significant correlation between erythrocyte n-3
long-chain PUFA content and compliance in resistance
arteries (C2), which was more closely associated with DHA
than EPA.
Similarly, n-3 long-chain PUFA supplementation in the
present study did not elicit any change in CRP, but erythrocyte
n-3 long-chain PUFA levels, particularly DHA, were inversely
associated with serum CRP. CRP is an acute phase protein
marker of systemic inflammation and is a predictor of cardio-
vascular risk. Previous studies have also shown an inverse
relationship between n-3 PUFA (a-linolenic acid, DHA and
EPA) and CRP levels (Lopez-Garcia et al. 2004). The findings
herein are similar to those of Geelen et al. (2004) who showed
no change in CRP following 12 weeks of supplementation
with 3·5 g fish oil/d (1·5 g/d n-3 PUFA). Furthermore, Mori
et al. (2003) supplemented the diets of fifty-nine non-smoking,
treated-hypertensive, type 2 diabetic subjects with 4 g of puri-
fied EPA or DHA for 6 weeks and showed no changed in
CRP. Similarly, Madsen et al. (2003) showed that 12 weeks
of supplementation with either a high dose (6·6 g) or low
dose (2 g) of n-3 long-chain PUFA had no effect on CRP.
However, our data support an anti-inflammatory effect of
n-3 long-chain PUFA in subjects with cardiovascular risk fac-
tors which may decrease the risk of CVD.
We showed no significant change in urinary 11-dehydro-
TXB2 following increased consumption of n-3 long-chain
PUFA. However, we demonstrated that erythrocyte n-3 long-
chain PUFAwere significantly inversely associatedwith urinary
11-dehydro-TXB2. These findings are in accordance with the
antithrombotic benefits of n-3 long-chain PUFA that are in
part related to their antiplatelet effects (Knapp, 1997). Mori
et al. (1997) showed that n-3 long-chain PUFA reduced ex
vivo platelet aggregation in response to collagen and platelet-
activating factor stimulation. Others have shown reduced
aggregatory responses to ADP, thrombin and adrenalin
(Kristensen et al. 1989). Moreover, DHA and not EPA reduced
collagen-induced platelet aggregation in type 2 diabetic patients
(Woodman et al. 2003). The reduction in platelet aggregation
was shown to be mediated largely by decreased platelet TXB2
release (Woodman et al. 2003). Others have demonstrated a
reduction in urinary TXB2 following higher intakes of n-3
long-chain PUFA (von Schacky & Weber, 1985).
In summary, regular consumption of foods enriched with
n-3 long-chain PUFA for 6 months increased erythrocyte
n-3 long-chain PUFA to levels consistent with a reduction in
cardiovascular risk (Harris & Von Schacky, 2004), although
there were no improvements in plasma lipids, BP or arterial
n-3-enriched foods and erythrocyte n-3 long-chain PUFA 755
compliance. Nevertheless, the level of n-3 long-chain PUFA,
specifically DHA, in erythrocytes was positively associated
with arterial compliance and negatively associated with both
serum CRP and 11-dehydro-urinary TXB2. These potentially
beneficial relationships warrant further investigation.
Acknowledgements
This study was funded by an Australian Research Council
Linkage Grant with Goodman Fielder Pty Ltd. We thank
Dr Geoffrey Annison, Geoff Weldon, Donna Ross and Coral
Colyer (formerly of Goodman Fielder Foods Ltd, Sydney)
for their contribution to the study design and development,
and provision of study foods; Jennifer Keogh, Paul Foster,
Jane Bowen, Lisa Moran for their assistance with diet consul-
tations; laboratory staff at CSIRO (Adelaide) and the School
of Medicine and Pharmacology (Western Australia).
References
Baghurst K (2005) Executive Summary of Nutrient Reference Values for
Australia and New Zealand including Recommended Dietary Intakes.
Commonwealth Department of Health and Ageing, Australia. Ministry
of Health, New Zealand. National Health and Medical Research
Council. http://www.nhmrc.gov.au/publications/synopses/n35syn.htm-
24k-[html]. Accessed 17 October 2006.
Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F &
Franceschini G (2004) An omega-3 polyunsaturated fatty acid con-
centrate increases plasma high-density lipoprotein 2 cholesterol
and paraoxonase levels in patients with familial combined hyperli-
pidemia. Metabolism 53, 153–158.
Christensen JH (2003) n-3 fatty acids and the risk of sudden cardiac
death. Emphasis on heart rate variability. Dan Med Bull 50,
347–367.
Dolecek T (1992) Epidemiological evidence of relationships between
dietary polyunsaturated fatty acids and mortality in the Multiple
Risk Factor Intervention Trial. Proc Soc Exp Biol Med 200,
177–182.
Friedewald WT, Levy RI & Fredrickson DS (1972) Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem 18,
499–502.
Geelen A, Brouwer IA, Schouten EG, Kluft C, Katan MB & Zock PL
(2004) Intake of n-3 fatty acids from fish does not lower serum
concentrations of C-reactive protein in healthy subjects. Eur J
Clin Nutr 58, 1440–1442.
Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR & Kok FJ (2002)
Blood pressure response to fish oil supplementation: meta-
regression analysis of randomized trials. J Hypertens 20,
1493–1499.
GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto miocardico) (1999) Dietary
supplementation with n-3 polyunsaturated fatty acids and vitamin
E after myocardial infarction: results of the GISSI-Prevenzione
trial. Lancet 354, 447–455.
Harris WS & Von Schacky C (2004) The Omega-3 Index: a new risk
factor for death from coronary heart disease? Prev Med 39,
212–220.
Howe PR, Downing JA, Grenyer BF, Grigonis-Deane EM & Bryden
WL (2002) Tuna fishmeal as a source of DHA for n-3 PUFA
enrichment of pork, chicken, and eggs. Lipids 37, 1067–1076.
Howe P, Meyer B, Record S & Baghurst K (2006) Dietary intake of
long-chain omega-3 polyunsaturated fatty acids: contribution of
meat sources. Nutrition 22, 47–53.
Hu FB & Willett WC (2002) Optimal diets for prevention of coronary
heart disease. J Am Med Assoc 288, 2569–2578.
Junker R, Pieke B, Schulte H, Nofer R, Neufeld M, Assmann G &
Wahrburg U (2001) Changes in hemostasis during treatment of
hypertriglyceridemia with a diet rich in monounsaturated and n-3
polyunsaturated fatty acids in comparison with a low-fat diet.
Thromb Res 101, 355–366.
Kolanowski W, Swiderski F, Lis E & Berger S (2001) Enrichment of
spreadable fats with polyunsaturated fatty acids omega-3 using fish
oil. Int J Food Sci Nutr 52, 469–476.
Knapp HR (1997) Dietary fatty acids in human thrombosis and
hemostasis. Am J Clin Nutr 65, 1687S–1698S.
Kristensen SD, Schmidt EB & Dyerberg J (1989) Dietary supplemen-
tation with n-3 polyunsaturated fatty acids and human platelet
function: a review with particular emphasis on implications for car-
diovascular disease. J Intern Med Suppl 731, 141–150.
Laidlaw M & Holub BJ (2003) Effects of supplementation with fish
oil-derived n-3 fatty acids and gamma-linolenic acid on circulating
plasma lipids and fatty acid profiles in women. Am J Clin Nutr 77,
37–42.
Lepage G & Roy CC (1986) Direct transesterification of all classes of
lipids in a one-step reaction. J Lipid Res 27, 114–120.
Lewis NM, Seburg S & Flanagan NL (2000) Enriched eggs as a
source of n-3 polyunsaturated fatty acids for humans. Poult Sci
79, 971–974.
Lopez-Ferrer S, Baucells MD, Barroeta AC & Grashorn MA (2001)
n-3 enrichment of chicken meat. 1. Use of very long-chain fatty
acids in chicken diets and their influence on meat quality: fish
oil. Poult Sci 80, 741–752.
Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM,
Rifai N, Willett WC & Hu FB (2004) Consumption of (n-3)
fatty acids is related to plasma biomarkers of inflammation and
endothelial activation in women. J Nutr 134, 1806–1811.
Lovegrove JA, Brooks CN, Murphy MC, Gould BJ & Williams CM
(1997) Use of manufactured foods enriched with fish oils as a
means of increasing long-chain n-3 polyunsaturated fatty acid
intake. Br J Nutr 78, 223–236.
Madsen T, Christensen JH, Blom M & Schmidt EB (2003) The effect
of dietary n-3 fatty acids on serum concentrations of C-reactive
protein: a dose-response study. Br J Nutr 89, 517–522.
Mantzioris E, Cleland LG, Gibson RA, Neumann MA, Demasi M &
James MJ (2000) Biochemical effects of a diet containing
foods enriched with n-3 fatty acids. Am J Clin Nutr 72, 42–48.
McLennan P, Howe P, Abeywardena M, Muggli R, Raederstorff D,
Mano M, Rayner T & Head R (1996) The cardiovascular
protective role of docosahexaenoic acid. Eur J Pharmacol 300,
83–89.
Metcalf RG, James MJ, Mantzioris E & Cleland LG (2003) A prac-
tical approach to increasing intakes of n-3 polyunsaturated fatty
acids: use of novel foods enriched with n-3 fats. Eur J Clin Nutr
57, 1605–1612.
Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ & Howe PR
(2003) Dietary intakes and food sources of omega-6 and omega-3
polyunsaturated fatty acids. Lipids 38, 391–398.
Mori TA, Beilin LJ, Burke V, Morris J & Ritchie J (1997) Inter-
actions between dietary fat, fish, and fish oils and their effects on
platelet function in men at risk of cardiovascular disease. Arterios-
cler Thromb Vasc Biol 17, 279–286.
Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD & Beilin LJ
(2003) Effect of eicosapentaenoic acid and docosahexaenoic
acid on oxidative stress and inflammatory markers in treated-
hypertensive type 2 diabetic subjects. Free Radic Biol Med 35,
772–781.
Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M & Raederstorff D
(2002) The n-3 fatty acids eicosapentaenoic acid and docosahexa-
enoic acid increase systemic arterial compliance in humans. Am J
Clin Nutr 76, 326–330.
K. J. Murphy et al.756
Ollis TE, Meyer BJ & Howe PR (1999) Australian food sources and
intakes of omega-6 and omega-3 polyunsaturated fatty acids. Ann
Nutr Metab 43, 346–355.
Patch CS, Tapsell LC, Mori TA, Myer BJ, Murphy KJ, Mansour J,
et al. (2005) The use of novel foods enriched with long-chain
n-3 fatty acids to increase dietary intake: a comparison of method-
ologies assessing nutrient intake. J Am Diet Assoc 105,
1918–1926.
Perneby C, Granstrom E, Beck O, Fitzgerald D, Harhen B &
Hjemdahl P (1999) Optimization of an enzyme immunoassay for
11-dehydro-thromboxane B(2) in urine: comparison with GC-MS.
Thromb Res 96, 427–436.
Roche H & Gibney M (1994) The effect of consumption of fish
oil-enriched spreadable fats on platelet phospholipid fatty acid
composition in human volunteers. Int J Vitam Nutr Res 64,
237–242.
Roche HM & Gibney MJ (1996) Postprandial triacylglycerolaemia:
the effect of low-fat dietary treatment with and without fish oil sup-
plementation. Eur J Clin Nutr 50, 617–624.
USFDA Letter Responding to Health Claim Petition dated November
3 2003 (Martek Petition): Omega-3 Fatty Acids and Reduced Risk
of Coronary Heart Disease, Office of Nutritional Products, Label-
ing and Dietary Supplements, September 8, 2004 (Docket
2003Q-0401).
Visioli F, Rise P, Plasmati E, Pazzucconi F, Sirtori CR & Galli C
(2000) Very low intakes of N-3 fatty acids incorporated into
bovine milk reduce plasma triacylglycerol and increase HDL-
cholesterol concentrations in healthy subjects. Pharmacol Res 41,
571–576.
von Schacky C & Weber PC (1985) Metabolism and effects on plate-
let function of the purified eicosapentaenoic and docosahexaenoic
acids in humans. J Clin Invest 76, 2446–2450.
Wallace JM, McCabe AJ, Robson PJ, Keogh MK, Murray CA, Kelly
PM, et al. (2000) Bioavailability of n-3 polyunsaturated fatty acids
(PUFA) in foods enriched with microencapsulated fish oil. Ann
Nutr Metab 44, 157–162.
Warnick GR & Albers JJ (1978) A comprehensive evaluation of the
heparin/manganese precipitation procedure for estimating HDL
cholesterol. J Lipid Res 9, 65–76.
Weber P & Raederstorff D (2000) Triglyceride-lowering effect of
omega-3 long-chain-polyunsaturated fatty acids—a review. Nutr
Metab Cardiovasc Dis 10, 28–37.
Wijendran V & Hayes KC (2004) Dietary n-6 and n-3 fatty acid bal-
ance and cardiovascular health. Annu Rev Nutr 24, 597–615.
Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF &
Beilin LJ (2003) Effects of purified eicosapentaenoic acid and doc-
osahexaenoic acid on platelet, fibrinolytic and vascular function in
hypertensive type 2 diabetic patients. Atherosclerosis 166, 85–93.
Yep YL, Li D, Mann NJ, Bode O & Sinclair AJ (2002) Bread
enriched with microencapsulated tuna oil increases plasma docosa-
hexaenoic acid and total omega-3 fatty acids in humans. Asia Pac J
Clin Nutr 11, 285–291.
n-3-enriched foods and erythrocyte n-3 long-chain PUFA 757
